September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
September 2023 in “Medicina Estética Revista Científica de la Sociedad Española de Medicina Estética (SEME)” The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
12 citations
,
May 2023 in “Molecules” Polygoni Cuspidati Rhizoma et Radix contains compounds that inhibit certain enzymes.
January 2017 in “Journal of Pakistan Association of Dermatologists” 1 citations
,
January 2012 in “Analytical chemistry, an Indian journal” A reliable method was developed to accurately measure tamsulosin hydrochloride and finasteride in tablets.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
March 2021 in “AACE clinical case reports” A man with both Klinefelter syndrome and primary hyperparathyroidism showed a rare combination of symptoms and genetic patterns.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
January 2004 in “Chinese Journal of New Drugs and Clinical Remedies” 
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
5 citations
,
August 1998 in “PubMed” Intravenous cyclophosphamide effectively treated steroid-resistant lupus cystitis and peritonitis.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.
August 2022 in “Nature Biotechnology” Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
4 citations
,
November 2021 in “Journal of Cosmetic Dermatology” QR678 and QR678 Neo treatments, combined with corticosteroid injections, work better for alopecia areata than corticosteroid injections alone.
13 citations
,
March 2021 in “British Journal of Pharmacology” KY19382 helps regrow hair and create new hair follicles.
January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
83 citations
,
October 2012 in “International Journal of Oncology” Wedelolactone selectively kills prostate cancer cells without harming normal cells.
14 citations
,
January 2017 in “Annals of Dermatology” Low-dose methotrexate effectively regrows hair in many alopecia areata patients but can cause some side effects.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
402 citations
,
August 2011 in “Cancer research” Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.
June 2014 in “Reactions Weekly” August 2011 in “Reactions Weekly” 
January 2025 in “JAAD International” Bicalutamide added no extra benefit over minoxidil alone for female-pattern hair loss.
February 2021 in “European Chemical Bulletin” A reliable method was developed to measure Minoxidil and Finasteride accurately in medicines.
April 2015 in “Reactions Weekly” May 2013 in “Reactions Weekly” December 2012 in “Reactions Weekly” January 2009 in “Reactions Weekly” January 2014 in “Reactions Weekly”